Selective, Micropulse and Pattern Laser Trabeculoplasty in Medically Treated Open-angle Glaucoma. (NCT07756411) | Clinical Trial Compass
CompletedNot Applicable
Selective, Micropulse and Pattern Laser Trabeculoplasty in Medically Treated Open-angle Glaucoma.
Italy90 participantsStarted 2025-02-01
Plain-language summary
This randomized, single-centre, three-arm trial compared three subvisible laser trabeculoplasty delivery protocols in eyes with open-angle glaucoma already receiving intraocular pressure (IOP)-lowering medication: selective laser trabeculoplasty (SLT, 3-nanosecond pulses), micropulse laser trabeculoplasty (MLT, 577 nm with 15% duty cycle), and pattern laser trabeculoplasty (PLT, 5-ms pattern delivery). Ninety eyes of 90 patients were allocated 1:1:1 to a single 360-degree session and followed for 6 months. The primary outcome was IOP at 6 months, with an equivalence margin of +/-2.0 mmHg prespecified for pairwise comparisons. Secondary outcomes were percentage IOP change, number of IOP-lowering medications, cumulative treatment success (IOP reduction of at least 20% from baseline without an increase in medications), and adverse events. Outcome assessment was performed by a second ophthalmologist masked to allocation and to clinical history.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* adults with primary or secondary open-angle glaucoma.
* gonioscopically open angle confirmed by gonioscopy in the study eye.
* receiving intraocular pressure-lowering medication at entry, with an indication for subvisible laser trabeculoplasty according to standard practice at the unit (IOP inadequately controlled on medical therapy, intolerance of medical therapy, or both).
* written informed consent.
Exclusion Criteria:
* previous laser trabeculoplasty, iridotomy or iridoplasty.
* corneal disease precluding visualization of the trabecular meshwork or reliable applanation tonometry.
* previous intraocular surgery other than uncomplicated cataract extraction.
* systemic medication known to affect intraocular pressure.
* pregnancy.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.